Interesting presentation although it doesn't include any results theirs still a few gems
- Checkvacc will only be going to cohort 6 by the looks of the updated dosing slide instead of the original 8
- Oncarlytics will only have 3 cohorts before expanding to a RP2D Expansion and will start at 10^7
- Also appears that this is the first time that Imugene have outlined some sort of commercial pathway in which they are trying to attract partners.
- Vaxinia Mono appears to be i the last cohort (presumably OBD) as there are no further cohorts planned on the slides
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
36.5¢ |
Change
-0.010(2.67%) |
Mkt cap ! $80.20M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 38.5¢ | 36.5¢ | $342.6K | 922.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 138148 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 123242 | 2 |
View Market Depth
| Last trade - 16.10pm 21/07/2025 (20 minute delay) ? |
| IMU (ASX) Chart |